Compare COSM & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COSM | EDSA |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4M | 12.8M |
| IPO Year | 2013 | N/A |
| Metric | COSM | EDSA |
|---|---|---|
| Price | $0.50 | $1.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 616.4K | 28.5K |
| Earning Date | 11-17-2025 | 12-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $59,792,819.00 | N/A |
| Revenue This Year | $28.14 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.69 | N/A |
| 52 Week Low | $0.28 | $1.55 |
| 52 Week High | $1.32 | $4.49 |
| Indicator | COSM | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 38.52 | 29.73 |
| Support Level | $0.41 | $1.44 |
| Resistance Level | $0.46 | $1.82 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 37.87 | 11.84 |
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.